Literature DB >> 1641517

Amplification of a particular DNA sequence in Streptomyces ambofaciens RP181110 reversibly prevents spiramycin production.

A Dary1, N Bourget, N Girard, J M Simonet, B Decaris.   

Abstract

Streptomyces ambofaciens RP181110 produces the macrolide antibiotic spiramycin. After treatment with ethidium bromide, 7 strains presenting an amplified sequence of DNA (ADS) were found in its progeny. These ADS were localized within the same amplifiable region of the RP181110 genome. It has been established that these amplified strains were non-producers (Spi-) and that the loss of one particular ADS was correlated with restoration of spiramycin production. Genome rearrangements such as deletions were detected on the same side of the amplifiable region in both amplified and deamplified strains.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1641517     DOI: 10.1016/0923-2508(92)90039-q

Source DB:  PubMed          Journal:  Res Microbiol        ISSN: 0923-2508            Impact factor:   3.992


  4 in total

1.  Gene Overexpression in Streptomyces hygroscopicus Associated with DNA Amplification.

Authors:  Guangxiang Cao; Peipei Zhang; Yuanxin Gu; Xiuhua Pang
Journal:  Curr Microbiol       Date:  2017-06-06       Impact factor: 2.188

2.  Modulation of lipid metabolism and spiramycin biosynthesis in Streptomyces ambofaciens unstable mutants.

Authors:  C Schauner; A Dary; A Lebrihi; P Leblond; B Decaris; P Germain
Journal:  Appl Environ Microbiol       Date:  1999-06       Impact factor: 4.792

3.  Stimulation of genetic instability and associated large genomic rearrangements in Streptomyces ambofaciens by three fluoroquinolones.

Authors:  J N Volff; D Vandewiele; B Decaris
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

4.  Characterization of a glycosyl transferase inactivating macrolides, encoded by gimA from Streptomyces ambofaciens.

Authors:  A Gourmelen; M H Blondelet-Rouault; J L Pernodet
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.